Quelle place pour les industriels du médicament ou des dispositifs médicaux dans la formation des médecins oncologues ? Divorce ou simple PACS ?

After the Médiator® scandal and other political scandals that have pointed out the possible interaction of conflicts of interest in many situations, the necessity to clarify the relationship between drug companies and CME is evident. Today, the debate is still open, and practitioners are waiting for the laws that will organize the funding of French CME. [ABSTRACT FROM AUTHOR]